|
See related Puregon information |
|
|
|
Manufacturer |
MSD |
|
Distributor |
Zuellig |
|
Contents |
Recombinant FSH (follitropin β) |
|
Indications |
Anovulation (including polycystic ovarian disease, PCOD), in women who have been unresponsive to treatment w/ clomiphene citrate. Controlled ovarian stimulation to induce the development of multiple follicles in medically assisted reproduction programs.
Click to view Puregon detailed prescribing infomation |
|
Dosage |
The dosage should be adjusted individually depending on the ovarian response.
Click to view Puregon detailed prescribing infomation |
|
Overdosage |
View Puregon overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Ovarian, breast, uterine, pituitary or hypothalamic tumours. Pregnancy or lactation. Undiagnosed vag bleeding. Primary ovarian failure. Ovarian cysts or enlarged ovaries, not related to polycystic ovarian disease (PCOD). Sexual organ malformations incompatible w/ pregnancy. Uterine fibroid tumours incompatible w/ pregnancy.
Click to view Puregon detailed prescribing infomation |
|
Warnings |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Puregon detailed prescribing infomation |
|
Special Precautions |
Exclude presence of uncontrolled non-gonadal endocrinopathies.
Click to view Puregon detailed prescribing infomation |
|
Adverse Drug Reactions |
Ovarian hyperstimulation, bruising, pain, redness, swelling & itching, ectopic pregnancy, multiple gestations, arterio-thromboembolisms.
View ADR Monitoring Form |
|
Drug Interactions |
Concomitant use w/ clomiphene citrate may enhance the follicular response. A higher dose may be needed after pituitary desensitisation induced by a GnRH agonist.
View more drug interactions with Puregon |
|
Pregnancy Category (US FDA) |
Category X: Studies in animals or human beings have demonstrated foetal abnormalities or there is evidence of foetal risk based on human experience or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant. |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Puregon detailed prescribing infomation |
|
Storage |
View Puregon storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Puregon description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Puregon mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
